• Aifa: almost 8,000 monoclonal antibodies prescribed, + 30% in 7 days

  • Covid: Ema, review on AstraZeneca monoclonals

  • Covid, the EMA approves 2 drugs based on monoclonal antibodies

Share

December 16, 2021 The European Medicines Agency has recommended the authorization of two new treatments for Covid-19.



Xevudy (sotrovimab), a monoclonal antibody, is indicated for the treatment of Covid-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of having the disease becomes severe.



Kineret (anakinra) is an immunosuppressive medicine already authorized in the EU for the treatment of various inflammatory conditions.

Its indication has now been extended to include Covid-19 treatment in adult patients with pneumonia who require supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPar (soluble urokinase plasminogen activator receptor).

Keywords: